Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine

European Journal of Neurology

Volumn 21, Issue 3, 2014, Pages 454-458

  Pedersen, E G ^a   Pottegard A ^b   Hallas, J ^b   Friis, S ^c   Hansen, K ^d   Jensen, P E H ^d   Gaist, D ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d University of Copenhagen   (Denmark)

Author keywords

Case control studies; Epidemiology; Myasthenia; Oncology

Indexed keywords

CASE-CONTROL STUDIES; EPIDEMIOLOGY; MYASTHENIA; ONCOLOGY;

AZATHIOPRINE; CASE-CONTROL STUDIES; COMMUNITY HEALTH PLANNING; CONFIDENCE INTERVALS; DENMARK; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOGISTIC MODELS; MALE; MYASTHENIA GRAVIS; ODDS RATIO; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84893871133     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12329     Document Type: Article

References (24)

1. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893-902.
2. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-1874.
3. Attard NR, Karran P. UVA photosensitization of thiopurines and skin cancer in organ transplant recipients. Photochem Photobiol Sci 2012; 11: 62-68.
4. IARC. A Review of Human Carcinogens. Part A: Pharmaceuticals, Vol. 100A. Lyon: International Agency for Research on Cancer, 2008: 319-331.
5. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011; 141: 1612-1620.
6. Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012; 27: 385-389.
7. Peyrin-Biroulet L, Khosrotehrani K, Carrat F. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-1628.
8. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B. Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased. Clin Gastroenterol Hepatol 2011; 9: 449-450.
9. Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis 2001; 27: 750-756.
10. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692-701.
11. Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Identifying patients with myasthenia for epidemiological research by linkage of automated registers. Neuroepidemiology 2011; 37: 120-128.
12. Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996-2009. Eur J Neurol 2013; 20: 309-314.
13. Gaist D, Andersen L, Hallas J, Sørensen HT, Schrøder HD, Friis S. Use of statin and risk of glioma: a nationwide case-control study in Denmark. Br J Cancer 2013; 108: 715-720.
14. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39(7 Suppl): 22-25.
15. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39(7 Suppl): 30-33.
16. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39(7 Suppl): 38-41.
17. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39(7 Suppl): 42-45.
18. Bjerregaard B, Larsen OB. The Danish Pathology Register. Scand J Public Health 2011; 39(7 Suppl): 72-74.
19. Pedersen EG, Pottegård A, Hallas J, et al. Use of azathioprine in non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. Eur J Neurol 2013; 20: 942-948.
20. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, 3rd edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2008: 124-125.
21. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics 2000; 56: 645-646.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
23. Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: 'the number of patients needed to be treated for one additional patient to be harmed'. BMJ 2000; 320: 503-506.
24. Danish Board of Health. The Danish Cancer Registry 2009 [In Danish]. Copenhagen: Danish Board of Health, 2010. www.sst.dk (accessed 05/01/2013).